Online inquiry

IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5107MR)

This product GTTS-WQ5107MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5107MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14490MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ10498MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ10055MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ10286MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ2918MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG888
GTTS-WQ11725MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
GTTS-WQ8813MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ14661MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW